Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 487-498 , August 2009

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

  • Bo Ahrén, MD, PhD (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +4646 2220758; Fax: +4646 2220757.

References 

  1. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Current Medical Research and Opinion. 2008;24:489–496
  2. Ahrén B. Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy. 2008;5:79–90
  3. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry. 2006;48:5025–5037
  4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  5. Ahrén B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays. 1998;20:642–651
  6. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48:1700–1713
  7. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Hormone and Metabolic Research. 2004;36:804–810
  8. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965
  9. Nyström T, Gutniak M, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. The American Journal of Physiology. 2004;287:E1209–E1215
  10. Ahrén B. Exenatide: a novel treatment of type 2 diabetes. Therapy. 2005;2:207–222
  11. Ahrén B. DPP-4 inhibitors. Best Practice & Research. Clinical Endocrinology & Metabolism. 2007;21:517–533
  12. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007;30:1344–1350
  13. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and Metabolic Research. 2004;36:867–876
  14. Mentlein R. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regulatory Peptides. 1999;85:9–24
  15. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–1864
  16. Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2078–2084
  17. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4888–4894
  18. Ahrén B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936–1940
  19. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564–2571
  20. Ahrén B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Hormone and Metabolic Research. 2007;39:826–829
  21. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism. 2007;92:12249–12255
  22. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care. 2002;25:869–875
  23. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2007;9:186–193
  24. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704
  25. Ahrén B, Sörhede Winzell M, Wierup N, et al. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell specific overexpression of human islet amyloid polypeptide. Regulatory Peptides. 2007;143:97–103
  26. Azuma K, Radikova Z, Mancino JM, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2008;93:459–464
  27. Ristic S, Byiers S, Foley J, et al. Improved glucaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes, Obesity & Metabolism. 2005;7:692–698
  28. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Hormone and Metabolic Research. 2006;387:423–438
  29. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Research and Clinical Practice. 2007;76:132–138
  30. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24 week double-blind, randomized, placebo-controlled, multiple-dose study. Hormone and Metabolic Research. 2007;39:218–223
  31. Scherbaum WA, Schweizer A, Mari A etal. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes, Obesity & Metabolism 2008; 10: 1114–1124.
  32. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31:30–35
  33. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Current Medical Research and Opinion. 2007;23:1329–1339
  34. Scott R, Wu L, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice. 2007;61:171–180
  35. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–2637
  36. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2008;10:376–386
  37. Rosenstock J, Aguilar-Salinas CA, Klein E, et al. Once-daily saxagliptin monotherapy improves glycemic control in drug-naïve patients with type 2 diabetes. Diabetes. 2008;57(suppl. 1):A154
  38. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30:3017–3022
  39. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217–223
  40. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine. 2007;24:955–961
  41. Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874–2880
  42. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–895
  43. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–2643
  44. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987
  45. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week randomized, double-blind study. Diabetes, Obesity & Metabolism. 2008;10:82–90
  46. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity & Metabolism. 2007;9:194–205
  47. Scott R, Loeys T, Davies M.J et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2008; 10: 959–969.
  48. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity & Metabolism. 2007;9:166–174
  49. Rosenstock J, Brazg RG, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapy. 2006;28:1556–1568
  50. Garber A.J, Foley J.E, Banerji M.A etal. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes, Obesity & Metabolism 2008; 10: 1047–1056.
  51. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity & Metabolism. 2007;9:733–745
  52. Fonseca V, chweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycemic control in type 2 diabetes. Diabetologia. 2007;50:1148–1155
  53. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49:2049–2057
  54. Bosi E, Byiers SR, Cohen SE. Vildagliptin significantly decreases blood pressure in hypertensive patients with type 2 diabetes compared with metformin. Diabetes. 2007;56(suppl. 1):A139
  55. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Research and Clinical Practice. 2007;76:132–138
  56. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2009;94:1236–1243
  57. Novartis AG. New Galvus clinical data reinforces efficacy profile; safety update provided to regulatory agencies. Press Release. November 6, 2009;
  58. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity & Metabolism. 2008;10:545–555
  59. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–2994
  60. Burkey B.F, Hoffman P.K, Hassiepen U et-al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes, Obesity & Metabolism 2008; 10: 1057–1061.
  61. Migoya EM, Miller JL, Larson PJ, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complimentary effects to increase active GLP-1 concentrations. Diabetologia. 2008;50(suppl. 1):S52
  62. Hjøllund KR, Hughes TE, Deacon CF, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin increases portal concentrations of active GLP-1 to a greater extent than the peripheral concentration. Diabetes. 2008;57(suppl. 1):A411
  63. Piiteau S, Olver A, Kim SJ, et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochemical and Biophysical Research Communications. 2007;362:1007–1012
  64. Ahrén B, Hughes TE. Inhibition of DPP-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. 2005;146:2055–2059

PII: S1521-690X(09)00022-0

doi: 10.1016/j.beem.2009.03.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 487-498 , August 2009

Article Tools

* Image Usage & Resolution